1 / 12

Safety and Tolerability of Empagliflozin

Safety and Tolerability of<br> <br>Empagliflozin<br>(Jardiance)

anwerghanijaber
Download Presentation

Safety and Tolerability of Empagliflozin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. . Safety and Tolerability of Empagliflozin (Jardiance) Anwer Ghani FIBMS Iraq

  2. . Empagliflozin is a sodium–glucose cotransporter (linked transporter) 2 inhibitor: (SGLT2) inhibitor.It inhibits glucose reabsorption in renal tubules and increase urinary glucose excretion. The glycosuria is dose dependent.

  3. . SGLT2 demonstrated significant cardiovascular benefits making them attractive options for the management of Type 2 diabetes mellitus (T2DM).

  4. . The incidence of any AEs, AEs leading to treatment discontinuation, severe AEs, and serious AEs was similar to other treatment. A study.

  5. . The empagliflozin 10/25 mg group was not associated with a higher rate of confirmed hypoglycemia versus placebo. A study.

  6. . The incidence of events consistent with urinary tract infections (UTI) was also similar for the empagliflozin 10/25 mg group versus placebo (9.27 vs. 9.70/100 patient-years, respectively). Many studies.

  7. . History of UTI was identified as a risk factor for UTI during treatment.

  8. . Events consistent with genital infections occurred more frequently with empagliflozin 10/25 mg than placebo (3.54 vs. 0.95/100 patient-years, respectively).

  9. . The frequency of AEs consistent with volume depletion was similar across groups, but higher with empagliflozin 10/25 mg than placebo in patients aged 75 years and those on loop diuretics at baseline. A study.

  10. . Compared with DPP-4 inhibitors and GLP-1 agonists, SGLT-2 inhibitors were not associated with excess risk for severe UTIs (defined as hospitalization for UTI, sepsis with UTI, or pyelonephritis) or for outpatient UTIs. A very big study.

  11. . Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure ( reduced or preserved ejection fraction).

More Related